Navigation Links
Facet Solutions Enjoys Continued Clinical Success With the Anatomic Facet Replacement System (AFRS(TM))
Date:10/19/2007

LOGAN, Utah, Oct. 19 /PRNewswire/ -- Facet Solutions, Inc. announced today that John Regan, M.D., a board-certified orthopedic surgeon at Century City Doctors Hospital in Los Angeles, California; and Darryl DiRisio, M.D., associate professor and neurosurgeon at Albany Medical College, Albany, New York, successfully completed additional surgical procedures utilizing the company's Anatomic Facet Replacement System (AFRS(TM)) as part of an FDA approved IDE Clinical Trial.

The AFRS(TM) is the first anatomic facet replacement device designed to provide patients with lumbar spinal stenosis and facet degeneration a motion preserving alternative to fusion.

A fusion uses metal rods and screws to join vertebrae together. While most patients report pain relief after a spinal fusion, the surgery often eliminates flexibility and range of motion, and can cause unnecessary wear on other spinal levels. By contrast, the AFRS(TM) is designed to mimic normal motion and prevent adjacent level degeneration.

The AFRS(TM) is made of two highly polished cobalt chrome implants that articulate similar to other total joints that have been used successfully in hip and knee replacements for several decades

"Until recently, people suffering from chronic lower back pain caused by lumbar spinal stenosis had few treatment options," stated Dr. Regan. "Facet joint replacement utilizing the AFRS(TM) not only relieves low back pain but also has the potential to significantly improve the patients' flexibility and range of motion.

Dr. DiRisio noted that the use of facet joint replacement for the treatment of spinal stenosis following a spinal decompression is a notable advance in spinal surgery. "It offers surgeons an alternative treatment for patients who have suffered for years from this debilitating condition."

The public response overall to the AFRS(TM) clinical trial has been very strong. New clinical investigator, Kenneth Pettine, M.D., board-certified orthopedic surgeon with the Rocky Mountain Spine Arthoplasty Specialists in Loveland, Colorado is looking forward to offering this new treatment option to his patients.

"Recently, I hosted a local community presentation to educate patients on the advantages of this new technology," stated Dr. Pettine. "I was very pleased with the strong attendance and was encouraged that a third of the attendees had signed up to learn more about the AFRS(TM) trial. The potential for patients to maintain motion, and continue with the normal activities of daily living, is what I believe is driving the high level of interest in this trial."

Facet Solutions invites clinicians, medical facilities, and other interested parties to visit http://www.facetsolutions.com for specific information about the AFRS(TM) Clinical Trial.

Facet Solutions also invites patients who are interested in learning more about the AFRS(TM) clinical trial to visit http://www.stenosisrelief.com. To determine if they are eligible to participate in the trial, patients can also call 1-877-STUDY-25.

*Note: AFRS(TM) is an investigational device in the United States. It is limited by United States (U.S.) Federal Law for investigational use only.

About Facet Solutions

Facet Solutions, Inc. is a privately held, venture backed company that is focused on developing and commercializing surgical devices for the treatment of facet related spinal disorders. Facet Solutions has received venture capital from its partners De Novo Ventures, Pequot Ventures, and Spray Venture Partners. Facet Solutions is FDA registered and is certified to ISO 13485.


'/>"/>
SOURCE Facet Solutions, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
2. Ties Between Physicians and Drug Companies Still Too Strong: the Prescription Project Offers Solutions to Prevent Conflicts of Interest
3. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
4. Genetic Analysis Systems Enter the Clinical Mainstream
5. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
6. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
7. Sygnis Pharma AG announces date for presentation of clinical results
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
11. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)...  Glenmark Pharmaceuticals, a global pharmaceutical company, today ... fixed-dose combination of mometasone furoate (25 mcg) and ... nasal spray being studied for the treatment of ... recently completed Phase 3 trial assessing the efficacy ... mometasone, olopatadine or placebo. "We continue ...
(Date:3/29/2017)... New York , March 29, 2017 /PRNewswire/ ... recently published a report, which provides an exhaustive ... to the study, nearly 242 companies are functional ... fragmented and competitive. With the leading companies, such ... Purdue Pharma LP, focusing aggressively on various marketing ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "Global ... ... market to grow at a CAGR of 2.87% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... A recent Bellwether Education ... quality, the field must first improve teacher preparation program design. It then asserts ... and that decades of input- and outcome-based research has failed to improve teacher ...
(Date:3/28/2017)... ... March 28, 2017 , ... Greenfield Advisors ... brings his extensive knowledge of appraisals, property values, ad valorem taxation, and government ... valuation industry for more than 40 years. , “Ruel is a great addition ...
(Date:3/28/2017)... ... March 29, 2017 , ... Dr. Isabella Wentz, PharmD, FASCP, ... 9-part video series titled The Thyroid Secret. Dr. Wentz talked about journey and research ... the fact that medication IS NOT the only solution to deal with thyroid disease. ...
(Date:3/28/2017)... PA (PRWEB) , ... March 28, 2017 , ... ... for and by physicians, announced today the launch of a free, public-facing tool ... Via Cost Analyzer (VCA) was developed to provide comparative information to patients, providers, ...
(Date:3/28/2017)... ... , ... Usually, the impending arrival of warmer weather means the gleeful banishment ... double chin, this means more anxiety than elation. The cosmetic dermatology experts at Cosmetic ... double chin is undesirable,” Dr. Goldman said, “but it seems doubly so when the ...
Breaking Medicine News(10 mins):